Just reported
From Pfizer's results release of 3. November 2026; its quarterly report has since been filed.
Actual
16,58B $
-0,4 % y/y
+10 % q/q
Guided
—
No guide given
Actual
0,56 $
-9,7 % y/y
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →The themes Pfizer is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Die Umsatzanteile sind Schätzungen für year ended December 31, 2025, high confidence und keine Zahlen aus einem eingereichten Bericht.
Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.
Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.
Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.
Gebaut aus den eigenen Einreichungen von Pfizer Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
29,45 $+0,3 %Schluss 11. Nov.
Zahlen bis 27. September 2026, aus dem 10-Q vom 3. November 2026
Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.
Grade C
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 41 Quartalen der Notenhistorie von Pfizer Inc.. Die übrigen 39 reichen zurück bis November 2016.